Biotechnology
Compare Stocks
2 / 10Stock Comparison
XNCR vs ALKS
Revenue, margins, valuation, and 5-year total return — side by side.
Biotechnology
XNCR vs ALKS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $954M | $5.89B |
| Revenue (TTM) | $93M | $1.56B |
| Net Income (TTM) | $-172M | $153M |
| Gross Margin | 94.4% | 65.4% |
| Operating Margin | -144.7% | 12.3% |
| Forward P/E | — | 24.7x |
| Total Debt | $188M | $70M |
| Cash & Equiv. | $54M | $1.12B |
XNCR vs ALKS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Xencor, Inc. (XNCR) | 100 | 43.0 | -57.0% |
| Alkermes plc (ALKS) | 100 | 215.9 | +115.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: XNCR vs ALKS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
XNCR is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 13.7%, EPS growth 65.4%, 3Y rev CAGR -8.6%
- 14.8% 10Y total return vs ALKS's -7.7%
- 13.7% revenue growth vs ALKS's -5.2%
ALKS carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- Dividend streak 0 yrs, beta 1.06
- Lower volatility, beta 1.06, Low D/E 3.8%, current ratio 3.55x
- Beta 1.06, current ratio 3.55x
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 13.7% revenue growth vs ALKS's -5.2% | |
| Quality / Margins | 9.8% margin vs XNCR's -185.7% | |
| Stability / Safety | Beta 1.06 vs XNCR's 1.99, lower leverage | |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | +53.8% vs ALKS's +16.3% | |
| Efficiency (ROA) | 5.4% ROA vs XNCR's -20.5%, ROIC 18.9% vs -16.3% |
XNCR vs ALKS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
XNCR vs ALKS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
ALKS leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ALKS is the larger business by revenue, generating $1.6B annually — 16.8x XNCR's $93M. ALKS is the more profitable business, keeping 9.8% of every revenue dollar as net income compared to XNCR's -185.7%. On growth, ALKS holds the edge at +28.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $93M | $1.6B |
| EBITDAEarnings before interest/tax | -$127M | $212M |
| Net IncomeAfter-tax profit | -$172M | $153M |
| Free Cash FlowCash after capex | -$189M | $392M |
| Gross MarginGross profit ÷ Revenue | +94.4% | +65.4% |
| Operating MarginEBIT ÷ Revenue | -144.7% | +12.3% |
| Net MarginNet income ÷ Revenue | -185.7% | +9.8% |
| FCF MarginFCF ÷ Revenue | -2.0% | +25.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | +28.2% |
| EPS Growth (YoY)Latest quarter vs prior year | -159.1% | -4.1% |
Valuation Metrics
XNCR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | ||
|---|---|---|
| Market CapShares × price | $954M | $5.9B |
| Enterprise ValueMkt cap + debt − cash | $1.1B | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -10.49x | 24.70x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 17.20x |
| Price / SalesMarket cap ÷ Revenue | 7.60x | 3.99x |
| Price / BookPrice ÷ Book value/share | 1.52x | 3.28x |
| Price / FCFMarket cap ÷ FCF | — | 12.25x |
Profitability & Efficiency
ALKS leads this category, winning 9 of 9 comparable metrics.
Profitability & Efficiency
ALKS delivers a 8.8% return on equity — every $100 of shareholder capital generates $9 in annual profit, vs $-24 for XNCR. ALKS carries lower financial leverage with a 0.04x debt-to-equity ratio, signaling a more conservative balance sheet compared to XNCR's 0.30x. On the Piotroski fundamental quality scale (0–9), ALKS scores 7/9 vs XNCR's 3/9, reflecting strong financial health.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | -23.7% | +8.8% |
| ROA (TTM)Return on assets | -20.5% | +5.4% |
| ROICReturn on invested capital | -16.3% | +18.9% |
| ROCEReturn on capital employed | -21.6% | +14.2% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 7 |
| Debt / EquityFinancial leverage | 0.30x | 0.04x |
| Net DebtTotal debt minus cash | $134M | -$1.0B |
| Cash & Equiv.Liquid assets | $54M | $1.1B |
| Total DebtShort + long-term debt | $188M | $70M |
| Interest CoverageEBIT ÷ Interest expense | -0.98x | 32.30x |
Total Returns (Dividends Reinvested)
ALKS leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in ALKS five years ago would be worth $16,047 today (with dividends reinvested), compared to $3,275 for XNCR. Over the past 12 months, XNCR leads with a +53.8% total return vs ALKS's +16.3%. The 3-year compound annual growth rate (CAGR) favors ALKS at 4.5% vs XNCR's -21.9% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -12.8% | +25.0% |
| 1-Year ReturnPast 12 months | +53.8% | +16.3% |
| 3-Year ReturnCumulative with dividends | -52.4% | +14.3% |
| 5-Year ReturnCumulative with dividends | -67.2% | +60.5% |
| 10-Year ReturnCumulative with dividends | +14.8% | -7.7% |
| CAGR (3Y)Annualised 3-year return | -21.9% | +4.5% |
Risk & Volatility
ALKS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
ALKS is the less volatile stock with a 1.06 beta — it tends to amplify market swings less than XNCR's 1.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ALKS currently trades 96.5% from its 52-week high vs XNCR's 69.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.99x | 1.06x |
| 52-Week HighHighest price in past year | $18.69 | $36.60 |
| 52-Week LowLowest price in past year | $6.92 | $25.17 |
| % of 52W HighCurrent price vs 52-week peak | +69.6% | +96.5% |
| RSI (14)Momentum oscillator 0–100 | 53.4 | 66.6 |
| Avg Volume (50D)Average daily shares traded | 861K | 2.3M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates XNCR as "Buy" and ALKS as "Buy". Consensus price targets imply 148.5% upside for XNCR (target: $32) vs 24.6% for ALKS (target: $44).
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $32.33 | $44.00 |
| # AnalystsCovering analysts | 27 | 28 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.5% |
ALKS leads in 4 of 6 categories (Income & Cash Flow, Profitability & Efficiency). XNCR leads in 1 (Valuation Metrics).
XNCR vs ALKS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is XNCR or ALKS a better buy right now?
For growth investors, Xencor, Inc.
(XNCR) is the stronger pick with 13. 7% revenue growth year-over-year, versus -5. 2% for Alkermes plc (ALKS). Alkermes plc (ALKS) offers the better valuation at 24. 7x trailing P/E, making it the more compelling value choice. Analysts rate Xencor, Inc. (XNCR) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — XNCR or ALKS?
Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +60.
5%, compared to -67. 2% for Xencor, Inc. (XNCR). Over 10 years, the gap is even starker: XNCR returned +14. 8% versus ALKS's -7. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — XNCR or ALKS?
By beta (market sensitivity over 5 years), Alkermes plc (ALKS) is the lower-risk stock at 1.
06β versus Xencor, Inc. 's 1. 99β — meaning XNCR is approximately 88% more volatile than ALKS relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 30% for Xencor, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — XNCR or ALKS?
By revenue growth (latest reported year), Xencor, Inc.
(XNCR) is pulling ahead at 13. 7% versus -5. 2% for Alkermes plc (ALKS). On earnings-per-share growth, the picture is similar: Xencor, Inc. grew EPS 65. 4% year-over-year, compared to -34. 1% for Alkermes plc. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — XNCR or ALKS?
Alkermes plc (ALKS) is the more profitable company, earning 16.
4% net margin versus -73. 2% for Xencor, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -141. 4% for XNCR. At the gross margin level — before operating expenses — XNCR leads at 91. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — XNCR or ALKS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is XNCR or ALKS better for a retirement portfolio?
For long-horizon retirement investors, Alkermes plc (ALKS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.
06)). Xencor, Inc. (XNCR) carries a higher beta of 1. 99 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALKS: -7. 7%, XNCR: +14. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between XNCR and ALKS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.